ronifibrate

Ronifibrate is a small molecule hypolipidemic agent of the fibrate class, used primarily for the treatment of hyperlipidemias such as hypertriglyceridemia and mixed dyslipidemia. Chemically, it is a combined ester of clofibric acid and niacin (nicotinic acid) with 1,3-propanediol; after administration, it is hydrolyzed in the body to release both active acids. Its mechanism of action involves agonism at peroxisome proliferator-activated receptor alpha (PPARα), which leads to increased lipolysis and reduction in blood lipid levels. Ronifibrate was initially developed by Daiichi Sankyo and has been approved for use in some regions since at least 1985[3][4][5][7].

Brand names

Cloprane

Other names

Ronifibrato42597-57-9